Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Pluri Inc. announced that its subsidiary Cellav has completed U.S. cosmetic product listings for two flagship regenerative aesthetic products, Regenativo+ and Placento+. The listings clear the regulatory path for a commercial launch in the United States during 2026, marking the transition of Cellav from product development to commercialization.
Key figures
- Products listed
- 2
- Market size 2030
- $90 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.